130418-90-5

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-ethynyl-, 1,1-dimethylethyl ester, (2R)-
• Synonyms: 1-Pyrrolidinecarboxylic acid, 2-ethynyl-, 1,1-dimethylethyl ester, (2R)-;(R)-tert-butyl 2-ethynylpyrrolidine-1-carboxylate;(R)-1-Boc-2-Ethynylpyrrolidine;2-Ethynyl-pyrrolidine-1-carboxylic acid tert-butyl ester;1-tert-Butoxycarbonyl-2-ethynylpyrrolidine;tert-butyl (2R)-2-ethynylpyrrolidine-1-carboxylate
• CAS NO: 130418-90-5
• Molecular Formula: C₁₁H₁₇NO₂
• Molecular Weight: 195.26
• Mol File: 130418-90-5.mol
• Article Data: 36

Chemical Properties

• Boiling Point: 249℃
• Flash Point: 104℃
• Appearance: /
• Density: 1.04
• Vapor Pressure: 0.023mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-ethynyl-, 1,1-dimethylethyl ester, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-ethynyl-, 1,1-dimethylethyl ester, (2R)-(130418-90-5)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-ethynyl-, 1,1-dimethylethyl ester, (2R)-(130418-90-5)

Safety Data

• Hazardous Substances Data: 130418-90-5(Hazardous Substances Data)

Usage

General Description

1-Pyrrolidinecarboxylic acid, 2-ethynyl-, 1,1-dimethylethyl ester, (2R)- is a chemical compound that is commonly known as (R)-Pregabalin. It is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. It works by binding to calcium channels in the central nervous system, which reduces the release of neurotransmitters, such as glutamate, norepinephrine, and substance P. This leads to a decrease in the excitability of nerve cells and a reduction in the transmission of pain signals. It is important to note that (R)-Pregabalin should be used only as prescribed by a healthcare professional, as it can have significant side effects and interactions with other medications.

InChI:InChI=1/C11H17NO2/c1-5-9-7-6-8-12(9)10(13)14-11(2,3)4/h1,9H,6-8H2,2-4H3/t9-/m0/s1

Upstream product

• 130419-38-4 (S)-2-(2,2-dibromoethenyl)-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester 
• 109-72-8 n-butyllithium 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 558-13-4 carbon tetrabromide 
• 69610-41-9 Boc-L-Pro-H 
• 27491-70-9 dimethyl diazomethylphosphonate 
• 21047-57-4 diethyl (1-diazo-2-oxopropyl)phosphonate 
• 4202-14-6 dimethyl (2-oxopropyl)phosphonate 
• 147-85-3 L-proline 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 115186-37-3 tert-butyl (2S)-2-{[N-methoxy(N-methyl)amino]carbonyl}pyrrolidine-1-carboxylate 

Downstream Products

• 147402-52-6 A 79814 
• 147402-53-7 (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole 
• 130523-69-2 *,R^*)>-2-<3-(dimethylamino)-1-propynyl>-1-(3,3,3-trifluoro-2-methoxy-1-oxo-2-phenylpropyl)pyrrolidine 
• 130523-67-0 *,R^*)>-2-<3-(1-pyrrolidinyl)-1-propynyl>-1-(3,3,3-trifluoro-2-methoxy-1-oxo-2-phenylpropyl)pyrrolidine 
• 130523-70-5 *,S^*)>-2-<3-(dimethylamino)-1-propynyl>-1-(3,3,3-trifluoro-2-methoxy-1-oxo-2-phenylpropyl)pyrrolidine 
• 130523-68-1 *,S^*)>-2-<3-(1-pyrrolidinyl)-1-propynyl>-1-(3,3,3-trifluoro-2-methoxy-1-oxo-2-phenylpropyl)pyrrolidine 
• 1201915-86-7 (S)-2-(1-phenyl-1H-1,2,3-triazol-4-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1445590-37-3 (S)-tert-butyl 2-(1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)pyrrolidine-1-carboxylate 
• 881691-88-9 tert-butyl (S)-1-(4-(benzyloxy)benzyl)-2-((S)-2-ethynylpyrrolidin-1-yl)-2-oxoethylcarbamate 

Relevant articles and documents

The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors

A novel series of HIV-1 integrase strand transfer inhibitors were designed using the venerable two-metal binding pharmacophore model and incorporating structural elements from two different literature scaffolds. This manuscript describes a number of 8-hyd

From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs

The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5-methoxy-4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}methanone (6), a compound which emerged from our in-house research program. Compound 6 was shown to be a potent, brain-penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above-mentioned shortcomings resulted in the identification of (4-chloro-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1,2,4]triazol-3-yl]-pyrrolidin-1-yl}l-methanone (42), a DORA with improved in vivo efficacy compared to 6.

Synthesis and thermo-responsive behavior of helical polyacetylenes derived from proline

A series of optically active helical poly[(S)-2-ethynyl-N-aliphatic acylpyrrolidine] were efficiently synthesized from a commercially available biomass-based starting material, and that bearing a short propionyl substituent exhibited an unexpected lower critical solution temperature in an aqueous solution with a narrow phase-transition window and a small hysteresis.